#melanoma

Immunotherapy Combo Improves Melanoma That Has Spread to Brain

People with mutations that lead to excessively long chromosome tips, or telomeres, may be at increased risk for a range of cancers.

Mara Eva Cline uses her platform to advocate for melanoma awareness. She also wrote a children’s book on skin cancer and sun safety.

The Melanoma Research Alliance looks at the benefits and challenges of a cellular therapy using tumor-infiltrating lymphocytes (TIL).

Leah Adams, 29, of Cleveland, is a Stage I melanoma survivor. She also helps care for her dad, who has Stage IV of the same skin cancer.

To honor a father and uncle lost to skin cancer, owners of racehorse Hot Rod Charlie put part of his winnings toward melanoma research.

Raise awareness of this skin cancer throughout May with the Melanoma Research Alliance. Check out our calendar of events.

Targeted therapies are an important part of the melanoma treatment arsenal, but where do they fit within the standard of care?

Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.

Desmoplastic melanoma, characterized by a high tumor mutation burden, may be uniquely sensitive to immune checkpoint inhibitors.

Topics discussed include brain metastases, emerging therapies, quality of life, the melanoma standard of care and more.

Research on metastatic melanoma suggests it may be possible to prevent some cancers from ever becoming resistant to targeted therapies.

After radiation, immunotherapy and chemo for melanoma, he tried an experimental therapy that uses TILs, tumor-infiltrating lymphocytes.

Sun exposure is the one risk factor for melanoma that people can control.

The BNT111-01 clinical trial explores an mRNA melanoma vaccine on its own and in combination with a PD-1 checkpoint immunotherapy.

For people who are newly diagnosed or undergoing active treatment, there is little specific dietary guidance, but new evidence is emerging.

Immunotherapy and … nothing else? Studies test a potential paradigm shift in treatment for some people with early stage cancers.